The Latest Cardiac and Vascular News
Modern Heart and Vascular Institute is proud to offer an intensive cardiac rehabilitation program designed to help patients get back to their normal lives after being diagnosed with cardiovascular disease. HUMBLE, Texas, Aug. 08, 2022 (GLOBE NEWSWIRE) — Modern Heart and Vascular is now offering intensive cardiac rehabilitation for patients […]
SUWANEE, GA, Aug. 08, 2022 (GLOBE NEWSWIRE) — via NewMediaWire – SANUWAVE Health, Inc. (OTCPK: SNWV), a leading provider of next-generation FDA-approved wound care products, today announced the closing of its $12 million private placement. Use of proceeds is to expand production capacity to meet demand, pay off an existing debt facility, […]
Successfully met the primary endpoint in the BrigHtn trial, delivering a 20.3 mmHg reduction in systolic blood pressure (SBP), or an 11 mmHg (p-value < 0.0001) decline on a placebo-adjusted basis, at 2 mg dose Independent Data Review Committee determined that the trial met pre-specified statistical criteria of overwhelming efficacy […]
Positive topline data in the Phase 2 BrigHtn trial, demonstrating clinically meaningful and statistically significant reduction in blood pressure with baxdrostat in treatment-resistant hypertension Completed enrollment in the HALO Phase 2 trial for baxdrostat in patients with uncontrolled hypertension with 249 patients randomized; topline data expected in the second half […]
SUWANEE, GA, Aug. 08, 2022 (GLOBE NEWSWIRE) — via NewMediaWire – SANUWAVE Health, Inc. (OTCPK: SNWV), a leading provider of next-generation wound care products, is pleased to announce the appointment of Mr. Morgan C. Frank as new Board Chairman effective today, August 5, 2022. Mr. Frank has been a principal at the life […]
ATLANTA, Aug. 4, 2022 /PRNewswire/ — Second Quarter and Recent Business Highlights: Achieved revenue of $80.3 million in the second quarter 2022 versus $76.1 million in the second quarter of 2021, an increase of 6% on a GAAP basis and 9% on a non-GAAP constant currency basis Enrolled first patients in U.S. AMDS clinical trial, PERSEVERE […]
Conference call scheduled for 4:30 p.m. Eastern Time today WALTHAM, Mass., Aug. 4, 2022 /PRNewswire/ — Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative first-in-class medicines that meet significant unmet medical needs, today reported business updates and financial results for the second quarter ended June 30, 2022. “The […]
THOUSAND OAKS, Calif., Aug. 4, 2022 /PRNewswire/ — Amgen (NASDAQ:AMGN) today announced financial results for the second quarter of 2022. Key results include: Total revenues increased 1% to $6.6 billion in comparison to the second quarter of 2021, resulting from 3% growth in global product sales partially offset by lower Other Revenue from our […]
ANDOVER, Mass., Aug. 4, 2022 /PRNewswire/ — TransMedics Group, Inc. (“TransMedics”) (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart and liver failure, announced today the upsize and pricing of an underwritten public offering of 3,250,000 shares of its common stock at a price […]
ALAMEDA, Calif., Aug. 4, 2022 /PRNewswire/ — Penumbra, Inc. (NYSE: PEN), a global healthcare company focused on innovative therapies, today reported financial results for the second quarter ended June 30, 2022. Revenue of $208.3 million in the second quarter of 2022, an increase of 13.1%, or 15.3% in constant currency1, compared to the second quarter of […]
